Lumbar disc disease and Modic changes: understanding and treatment

You have just had a lumbar MRI and the radiologist’s report mentions “Modic type 1 changes” at L4-L5 or L5-S1. What does this mean? Is it serious? Will it get better? And above all, what can be done about it? Dr Christian Dimitriu, spine neurosurgeon in Paris, explains the mechanisms of lumbar disc degeneration, the significance of Modic changes and the evidence-based treatment options available.

What is lumbar disc disease?

The intervertebral disc acts as a shock absorber between two adjacent vertebrae. It is composed of a central gelatinous nucleus pulposus, rich in water and proteoglycans, surrounded by a fibrous ring called the annulus fibrosus. From the age of 25 to 30 onwards, the disc begins to lose water content — a process called desiccation — and progressively loses its height and mechanical properties.

This degenerative process, known as lumbar disc disease (or discopathy), is universal to some degree. However, in a proportion of individuals, it progresses to become a source of significant, chronic pain. Several factors accelerate disc degeneration:

• Genetic predisposition: disc degeneration runs strongly in families; heritability estimates reach 60 to 70%
• Mechanical overload: repetitive heavy lifting, prolonged axial loading, occupational exposure
• Smoking: impairs disc nutrition by reducing vascular supply to the endplates
• Obesity: increases load on lumbar segments
• Sedentary lifestyle: reduces disc hydration through lack of movement-driven fluid exchange

As the disc degenerates, the vertebral endplates — thin cartilaginous and bony layers separating the disc from the vertebral body — are subjected to abnormal mechanical stresses and can develop microfractures, oedema and ultimately structural changes visible on MRI. These endplate changes are what we call Modic changes.

What are Modic changes?

Modic changes were first described and classified by the American radiologist Michael T. Modic in 1988. They represent MRI signal abnormalities of the subchondral bone marrow immediately adjacent to a degenerated intervertebral disc. They are graded into three distinct types with different biological substrates, clinical presentations and prognoses.

Modic type 1 — active inflammation

On T1-weighted MRI sequences, the affected endplate area appears hypointense (dark); on T2-weighted sequences it appears hyperintense (bright). This pattern corresponds histologically to bone marrow oedema, vascularised fibrous tissue, microfractures of the endplate and active inflammation mediated by pro-inflammatory cytokines (IL-1β, TNF-α, IL-6).

Modic type 1 is the most clinically significant type. It is associated with:

• Intense, often debilitating low back pain with a strong inflammatory rhythm (worse on waking, morning stiffness >30 minutes, may improve with movement)
• Pain that tends to be mechanical and inflammatory combined — worsened by both prolonged rest and sustained loading
• High CRP in a minority of cases (if a low-grade infection is the driver)
• Dynamic nature: may evolve, regress or convert to Modic 2 over months to years

Modic type 2 — fatty replacement

Both T1 and T2 sequences show hyperintensity (bright signal), corresponding histologically to fatty replacement of the red bone marrow adjacent to the disc. This represents a more stable, chronic phase of the endplate response.

Modic type 2 is less acutely painful than type 1. Pain, when present, tends to be more constant and less inflammatory in character. Modic 2 changes are the most frequently encountered type on lumbar MRI in adults over 50 and represent the natural endpoint of the evolution from type 1.

Modic type 3 — bone sclerosis

Both T1 and T2 sequences show hypointensity (dark signal), corresponding to dense bone sclerosis (eburnation) of the subchondral endplate. This is the late, “burnt-out” stage of endplate degeneration. Modic type 3 is usually asymptomatic or only mildly symptomatic and has no specific treatment.

The Modic 1 – infection hypothesis

An important and still debated area is the potential role of low-grade bacterial infection in the pathogenesis of Modic type 1 changes. The hypothesis, first extensively investigated by Danish researcher Hanne Albert, proposes that disc herniation events allow anaerobic bacteria — principally Cutibacterium acnes (formerly Propionibacterium acnes), a skin commensal — to enter the disc via the bloodstream or directly, and establish a chronic low-grade infection within the avascular nucleus pulposus.

The resulting biofilm-driven chronic infection triggers endplate inflammation and the MRI changes characteristic of Modic 1. The landmark Albert 2013 randomised controlled trial (BMC Medicine) enrolled patients with chronic low back pain and Modic 1 changes following prior disc herniation, and randomised them to 100 days of amoxicillin-clavulanate (500/125 mg three times daily) versus placebo. At one year, the antibiotic group showed significantly greater improvements in pain, disability and leg pain scores.

This has given rise to the treatment protocol known as MAST (Modic Antibiotic Spine Therapy). However, several important caveats apply:

• The Albert trial has not been replicated consistently in subsequent studies
• No validated diagnostic test exists to confirm disc infection prior to treatment
• Long-course antibiotics carry risks of resistance, gastrointestinal side effects and C. difficile infection
• MAST is not a validated standard-of-care treatment in France or in international guidelines (HAS, NASS, EuroSpine)

Dr Dimitriu considers MAST an investigational approach, and its use requires rigorous patient selection, multidisciplinary discussion and informed consent regarding the uncertain evidence base.

Conservative treatment of lumbar disc disease with Modic changes

Modic type 1: anti-inflammatory and analgesic strategy

The cornerstone of treatment for Modic type 1 changes is effective anti-inflammatory therapy. NSAIDs taken on a scheduled basis (not on demand) provide meaningful pain relief and address the underlying inflammatory process. In cases of severe inflammatory flare, a short course of oral corticosteroids (5 to 7 days) can provide rapid relief.

Partial relative rest during the acute phase — reducing prolonged standing and heavy loading — is sensible, but strict bed rest is harmful and counterproductive. Lumbar physiotherapy, focusing on gentle stabilisation exercises and progressive loading, should begin as soon as the acute phase allows. This strengthens the paraspinal musculature and reduces mechanical stress on the affected segment.

Epidural corticosteroid injections (translaminar or transforaminal) can provide 6 to 12 weeks of significant pain relief in patients with associated radicular irritation, allowing a therapeutic window for rehabilitation.

Modic type 2: rehabilitation and chronic pain management

For patients with Modic type 2 changes, the emphasis shifts to active rehabilitation and long-term pain management. NSAIDs remain useful for flares, but the primary treatment is physiotherapy-based: lumbar stabilisation programmes, aquatic therapy, and progressive return to physical activity. A multidisciplinary pain programme (combining physiotherapy, cognitive-behavioural therapy and medical pain management) is indicated for patients with significant functional disability and psychological contributors to pain.

Modic type 3: symptomatic treatment only

Modic type 3 changes rarely require specific treatment. Analgesics for pain flares and general spinal physiotherapy are sufficient in most cases.

Natural history: do Modic changes evolve over time?

The natural history of Modic changes has been studied in several longitudinal MRI cohorts. The key findings are:

• Modic 1 → Modic 2 conversion: documented in a significant proportion of patients (estimates range from 20 to 50% over 2 years), often associated with clinical improvement as the inflammatory phase resolves
• Modic 1 partial regression: some lesions shrink or disappear spontaneously, particularly smaller ones
• Modic 2 stability: most type 2 changes persist long-term; conversion to type 3 occurs but is less common
• New Modic development: new endplate changes can appear at previously unaffected levels, especially in patients with multilevel disc disease

This dynamic natural history means that MRI surveillance (typically every 12 to 18 months for symptomatic Modic 1) is an important component of ongoing management, both to monitor progression and to reassess the appropriateness of treatment strategies.

When is surgery indicated?

Lumbar interbody fusion for discogenic low back pain with Modic changes is one of the most carefully debated indications in spine surgery. The evidence base for fusion in isolated low back pain is considerably weaker than for fusion combined with disc herniation or spinal stenosis. Current international guidelines (HAS, NASS, EuroSpine, AOSpine) recommend surgery only when all of the following criteria are met:

• Duration: at least 12 to 18 months of persistent, disabling low back pain
• Conservative treatment failure: documented failure of structured physiotherapy, NSAIDs, and at least one minimally invasive procedure (e.g., epidural injection)
• Radiological correlation: clear Modic 1 or 2 changes at the clinically symptomatic level on MRI; discography (provocative disc testing) may be used in selected cases to confirm the symptomatic disc, though its routine use is declining
• Functional disability: Oswestry Disability Index (ODI) ≥ 40%, significant impact on professional and personal activities
• Psychological readiness: no major unaddressed psychological or social barriers (depression, catastrophising, secondary gain) that would significantly impair surgical outcomes

The surgical procedure most commonly used is transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fusion (PLIF): the degenerated disc is removed, the endplates are carefully prepared, an interbody cage is inserted to restore disc height and promote fusion, and pedicle screws with rods are placed to provide rigid fixation. In carefully selected patients, success rates for meaningful pain reduction are approximately 60 to 70%, but patient selection is paramount.

Frequently asked questions

Sources: Modic MT et al., Radiology 1988 — Albert HB et al., BMC Medicine 2013 — Jensen MC et al., NEJM 1994 — Braithwaite I et al., Spine 1998 — HAS, EuroSpine, NASS guidelines on chronic low back pain — AOSpine.